Literature DB >> 18603452

Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles.

C Thouverey1, G Bechkoff, S Pikula, R Buchet.   

Abstract

OBJECTIVE: Pathological mineralization is induced by unbalance between pro- and anti-mineralization factors. In calcifying osteoarthritic joints, articular chondrocytes undergo terminal differentiation similar to that in growth plate cartilage and release matrix vesicles (MVs) responsible for hydroxyapatite (HA) or calcium pyrophosphate dihydrate (CPPD) deposition. Inorganic pyrophosphate (PP(i)) is a likely source of inorganic phosphate (P(i)) to sustain HA formation when hydrolyzed but also a potent inhibitor preventing apatite mineral deposition and growth. Moreover, an excess of PP(i) can lead to CPPD formation, a marker of pathological calcification in osteoarthritic joints. It was suggested that the P(i)/PP(i) ratio during biomineralization is a turning point between physiological and pathological mineralization. The aim of this work was to determine the conditions favoring either HA or CPPD formation initiated by MVs.
METHODS: MVs were isolated from 17-day-old chicken embryo growth plate cartilages and subjected to mineralization in the presence of various P(i)/PP(i) ratios. The mineralization kinetics and the chemical composition of minerals were determined, respectively, by light scattering and infrared spectroscopy.
RESULTS: The formation of HA is optimal when the P(i)/PP(i) molar ratio is above 140, but is completely inhibited when the ratio decreases below 70. The retardation of any mineral formation is maximal at P(i)/PP(i) ratio around 30. CPPD is exclusively produced by MVs when the ratio is below 6, but it is inhibited for the ratio exceeding 25.
CONCLUSIONS: Our findings are consistent with the P(i)/PP(i) ratio being a determinant factor leading to pathological mineralization or its inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18603452     DOI: 10.1016/j.joca.2008.05.020

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  36 in total

Review 1.  [Crystal arthropathies].

Authors:  M Fuerst; J Zustin; W Rüther
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

2.  Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia.

Authors:  Barry L Gruber; Ana Rita Couto; Jácome Bruges Armas; Matthew A Brown; Kathleen Finzel; Robert A Terkeltaub
Journal:  J Clin Rheumatol       Date:  2012-06       Impact factor: 3.517

3.  Connective tissue mineralization in Abcc6-/- mice, a model for pseudoxanthoma elasticum.

Authors:  N Beril Kavukcuoglu; Qiaoli Li; Nancy Pleshko; Jouni Uitto
Journal:  Matrix Biol       Date:  2012-03-06       Impact factor: 11.583

4.  Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.

Authors:  Yael Nadel; Joanna Lecka; Yocheved Gilad; Gal Ben-David; Daniel Förster; Georg Reiser; Sarah Kenigsberg; Jean Camden; Gary A Weisman; Hanoch Senderowitz; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2014-05-30       Impact factor: 7.446

5.  Phosphate regulates chondrogenesis in a biphasic and maturation-dependent manner.

Authors:  Biming Wu; Emily K Durisin; Joseph T Decker; Evran E Ural; Lonnie D Shea; Rhima M Coleman
Journal:  Differentiation       Date:  2017-05-08       Impact factor: 3.880

6.  Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Authors:  Lothar Seefried; Jasmin Baumann; Sarah Hemsley; Christine Hofmann; Erdmute Kunstmann; Beate Kiese; Yue Huang; Simon Chivers; Marie-Anne Valentin; Babul Borah; Ronenn Roubenoff; Uwe Junker; Franz Jakob
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

7.  Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis.

Authors:  Geraldine M McCarthy; Herman S Cheung
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 8.  Counterpoint: Hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis.

Authors:  Kenneth P H Pritzker
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  [Crystal arthropathies].

Authors:  M Fuerst; J Haybaeck; J Zustin; W Rüther
Journal:  Orthopade       Date:  2009-06       Impact factor: 1.087

Review 10.  Biophysical aspects of biomineralization.

Authors:  Maytê Bolean; Ana M S Simão; Marina B Barioni; Bruno Z Favarin; Heitor G Sebinelli; Ekeveliny A Veschi; Tatiane A B Janku; Massimo Bottini; Marc F Hoylaerts; Rosangela Itri; José L Millán; Pietro Ciancaglini
Journal:  Biophys Rev       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.